Lantheus (NASDAQ:LNTH) Share Price Breaks Above Fifty Day Moving Average – Here’s Why

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price passed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $100.25 and traded as high as $100.50. Lantheus shares last traded at $100.32, with a volume of 771,628 shares changing hands.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. TD Cowen downgraded Lantheus from a “buy” rating to a “hold” rating and dropped their price target for the company from $110.00 to $102.50 in a research report on Monday, August 3rd. CJS Securities cut Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. Mizuho cut shares of Lantheus from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $115.00 to $109.00 in a research report on Tuesday, October 13th. Leerink Partners set a $102.50 price objective on Lantheus in a report on Monday, August 3rd. Finally, Brookline Capital Markets downgraded shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Three investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $107.44.

Lantheus Stock Up 0.2%

The stock’s 50-day moving average price is $100.25 and its two-hundred day moving average price is $91.01. The stock has a market capitalization of $6.55 billion, a PE ratio of 24.23 and a beta of -0.06. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The company had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter last year, the company earned $1.57 EPS. As a group, analysts expect that Lantheus Holdings, Inc. will post 4.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of large investors have recently made changes to their positions in the company. ProShare Advisors LLC raised its position in Lantheus by 28.7% in the 3rd quarter. ProShare Advisors LLC now owns 14,317 shares of the medical equipment provider’s stock worth $1,425,000 after purchasing an additional 3,191 shares during the period. Vise Technologies Inc. lifted its stake in Lantheus by 80.8% in the third quarter. Vise Technologies Inc. now owns 8,196 shares of the medical equipment provider’s stock worth $816,000 after purchasing an additional 3,664 shares during the last quarter. WD Rutherford LLC boosted its position in shares of Lantheus by 88.0% during the third quarter. WD Rutherford LLC now owns 8,368 shares of the medical equipment provider’s stock valued at $833,000 after buying an additional 3,917 shares during the period. Peterson Wealth Services boosted its position in shares of Lantheus by 13.6% during the third quarter. Peterson Wealth Services now owns 10,549 shares of the medical equipment provider’s stock valued at $1,050,000 after buying an additional 1,265 shares during the period. Finally, Fifth Third Wealth Advisors LLC boosted its position in shares of Lantheus by 16.2% during the third quarter. Fifth Third Wealth Advisors LLC now owns 2,495 shares of the medical equipment provider’s stock valued at $248,000 after buying an additional 348 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.